Literature DB >> 1871717

Dependence of blood clot lysis on the mode of transport of urokinase into the clot--a magnetic resonance imaging study in vitro.

A Blinc1, G Planinsic, D Keber, O Jarh, G Lahajnar, A Zidansĕk, F Demsar.   

Abstract

Magnetic resonance imaging was employed to study the dependence of clot lysing patterns on two different modes of transport of urokinase into whole blood clots. In one group of clots (nonperfused clots, n1 = 10), access of urokinase to the fibrin network was possible by diffusion only, whereas in the other group (perfused clots, n2 = 10) bulk flow of plasma containing urokinase was instituted through occlusive clots by a pressure difference of 3.7 kPa (37 cm H2O) across 3 cm long clots with a diameter of 4 mm. It was determined separately that this pressure difference resulted in a volume flow rate of 5.05 +/- 2.4 x 10(-2) ml/min through occlusive clots. Perfused clots diminished in size significantly in comparison to nonperfused ones already after 20 min (p less than 0.005). Linear regression analysis of two-dimensional clot sizes measured by MRI showed that the rate of lysis was more than 50-times faster in the perfused group in comparison to the nonperfused group. It was concluded that penetration of the thrombolytic agent into clots by perfusion is much more effective than by diffusion. Our results might have some implications for understanding the differences in lysis of arterial and venous thrombi.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871717

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Augmentation of in-vitro clot dissolution by low frequency high-intensity ultrasound combined with antiplatelet and antithrombotic drugs.

Authors:  S Atar; H Luo; Y Birnbaum; T Nagai; R J Siegel
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

2.  Enhancement of fibrinolysis in vitro by ultrasound.

Authors:  C W Francis; P T Onundarson; E L Carstensen; A Blinc; R S Meltzer; K Schwarz; V J Marder
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

3.  Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Finger-like lysing patterns of blood clots.

Authors:  A Zidansek; A Blinc; G Lahajnar; D Keber; R Blinc
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

5.  Inner clot diffusion and permeation during fibrinolysis.

Authors:  S L Diamond; S Anand
Journal:  Biophys J       Date:  1993-12       Impact factor: 4.033

6.  An In Vitro Thrombolysis Study Using a Mixture of Fast-Acting and Slower Release Microspheres.

Authors:  Hoai X Nguyen; Edgar A O'Rear
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

7.  Association Between Serial Measures of Systemic Blood Pressure and Early Coronary Arterial Perfusion Status Following Intravenous Thrombolytic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

8.  Clot retraction affects the extent of ultrasound-enhanced thrombolysis in an ex vivo porcine thrombosis model.

Authors:  Jonathan T Sutton; Nikolas M Ivancevich; Stephen R Perrin; Deborah C Vela; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2013-03-01       Impact factor: 2.998

9.  Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.

Authors:  Shaul Atar; Yoram Neuman; Takashi Miyamoto; Ming Chen; Yochai Birnbaum; Huai Luo; Sergio Kobal; Robert J Siegel
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

10.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.